TITLE

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

AUTHOR(S)
Edan, G; Miller, D; Clanet, M; Confavreux, C; Lyon-Caen, O; Lubetzki, C; Brochet, B; Berry, I; Rolland, Y; Froment, J C; Cabanis, E; Iba-Zizen, M T; Gandon, J M; Lai, H M; Moseley, I; Sabouraud, O
PUB. DATE
February 1997
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Feb1997, Vol. 62 Issue 2, p112
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66125493

 

Related Articles

  • Mitoxantrone: a review of its use in multiple sclerosis. Scott, Lesley J.; Figgitt, David P. // CNS Drugs;2004, Vol. 18 Issue 6, p379 

    Mitoxantrone (Novantrone), a synthetic anthracenedione derivative, is an antineoplastic, immunomodulatory agent. Its presumed mechanism of action in patients with multiple sclerosis (MS) is via immunomodulatory mechanisms, although these remain to be fully elucidated. Intravenous mitoxantrone...

  • Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis. Debouverie, M.; Vandenberghe, N.; Morrissey, S. P.; Anxionnat, R.; Pittion-Vouyovitch, S.; Vespignani, H.; Edan, G. // Multiple Sclerosis (13524585);Aug2004, Vol. 10 Issue 4, p407 

    Introduction: In a number of controlled trials it was established that mitoxantrone has a beneficial effect on disease progression in multiple sclerosis (MS) patients with a worsening disease course. The aim of this study was to investigate the use of mitoxantrone in clinical practice, and...

  • Mitoxantrone reduces relapse rate and slows disease progression in worsening multiple sclerosis. Adis International Limited // Drugs & Therapy Perspectives;Mar2005, Vol. 21 Issue 3, p1 

    Discusses the effect of mitoxantrone, an anthracenedione derivative, on relapse rate and disease progression of multiple sclerosis. Description of the disease; Features and properties of mitoxantrone; Analysis of the clinical efficacy of the drug.

  • Induction Therapy for Patients with Multiple Sclerosis: Why? When? How? Edan, Gilles; Page, Emmanuelle // CNS Drugs;2013, Vol. 27 Issue 6, p403 

    The concept of induction treatment followed by long-term maintenance treatment in multiple sclerosis (MS) has attracted considerable attention. The combination of mitoxantrone as the induction therapy followed by an immunomodulatory drug (e.g., interferon beta or glatiramer acetate) as the...

  • Immunosuppression.  // Multiple Sclerosis (13524585);Sep2007 Supplement 2, Vol. 13, pS240 

    The article presents abstracts of medical research which include "Efficacy and safety of mitoxantrone in multiple sclerosis patients with different clinical courses," "Retrospective study to assess the effectiveness and safety profile of mitoxantrone in a Spanish cohort of multiple sclerosis...

  • Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone. Evdoshenko, Evgeniy; Maslyanskiy, Alexey; Lapin, Sergey; Zaslavsky, Leonid; Dobson, Ruth; Totolian, Areg; Skoromets, Alexander; Bar-Or, Amit // ISRN Neurology;2013, p1 

    Background. Mitoxantrone (MTX) and Rituximab (RTX) are successfully used for treatment of multiple sclerosis (MS) and can be combined to increase efficacy. Objective. We used MTX, RTX, and methylprednisolone in a single combined regiment and observed patients prospectively. Methods. We present...

  • What is New in the Treatment of Multiple Sclerosis? Weinstock-Guttman, B.; Jacobs, L.D. // Drugs;Mar2000, Vol. 59 Issue 3, p401 

    Multiple sclerosis (MS) is considered an autoimmune disease associated with immune activity directed against central nervous system antigens. Based on this concept, immunosuppression and immunomodualtion have been the mainstays of therapeutic strategies in MS. During the last decade new...

  • Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. Edan, G.; Comi, G.; Le Page, E.; Leray, E.; Rocca, M. A.; Filippi, M. // Journal of Neurology, Neurosurgery & Psychiatry;Dec2011, Vol. 82 Issue 12, p1344 

    Objectives The long-term impact of interferon-beta-1b (IFN) might be improved by short-term immunosuppression with mitoxantrone (MITOX) in aggressive relapsing-remitting multiple sclerosis (ARMS) patients. Methods In this 3-year clinical and MRI study, 109 ARMS patients (two or more relapses in...

  • Magnetic resonance imaging important research tool for MS. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;12/20/97, Vol. 10 Issue 12, p24 

    Reports that the magnetic resonance imaging (MRI) measures of disease activity is one of the end points on clinical studies of therapies for multiple sclerosis.

  • Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Capello, E.; Saccardi, R.; Murialdo, A.; Gualandi, F.; Pagliai, F.; Bacigalupo, A.; Marmont, A.; Uccelli, A.; Inglese, M.; Bruzzi, P.; Sormani, M.; Cocco, E.; Meucci, G.; Massacesi, L.; Bertolotto, A.; Lugaresi, A.; Merelli, E.; Solari, A.; Filippi, M.; Mancardi, G. // Neurological Sciences;Dec2005 Supplement 4, Vol. 26, ps200 

    Aggressive forms of multiple sclerosis (MS) represent a limited group of demyelinating diseases that rapidly progress to severe disability. Currently available therapies are poorly effective against these clinical entities. Recently, it has been demonstrated that intense immunosuppression...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics